BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31027693)

  • 1. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
    Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
    Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
    Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
    J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
    Wang X; Zamdborg L; Ye H; Grills IS; Yan D
    BMC Cancer; 2018 Oct; 18(1):962. PubMed ID: 30305131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
    von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
    Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
    Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
    Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Koshy M; Malik R; Weichselbaum RR; Sher DJ
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):344-50. PubMed ID: 25636759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage I Lung SBRT Clinical Practice Patterns.
    Corso CD; Park HS; Moreno AC; Kim AW; Yu JB; Husain ZA; Decker RH
    Am J Clin Oncol; 2017 Aug; 40(4):358-361. PubMed ID: 25503436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
    Ager BJ; Wells SM; Gruhl JD; Stoddard GJ; Tao R; Kokeny KE; Hitchcock YJ
    Lung Cancer; 2019 Dec; 138():6-12. PubMed ID: 31593894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definitive treatment patterns and survival in stage II non-small cell lung cancer.
    Yan SX; Qureshi MM; Suzuki K; Dyer M; Truong MT; Litle V; Mak KS
    Lung Cancer; 2018 Oct; 124():135-142. PubMed ID: 30268452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
    Tembhekar AR; Wright CL; Daly ME
    Clin Lung Cancer; 2017 May; 18(3):293-298. PubMed ID: 28089158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
    Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
    Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Body Radiation Therapy With a High Maximum Dose Improves Local Control, Cancer-Specific Death, and Overall Survival in Peripheral Early-Stage Non-Small Cell Lung Cancer.
    Tateishi Y; Takeda A; Horita N; Tsurugai Y; Eriguchi T; Kibe Y; Sanuki N; Kaneko T
    Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):143-151. PubMed ID: 33891980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions.
    Ding M; Zollinger W; Ebeling R; Heard D; Posey R
    J Appl Clin Med Phys; 2018 Nov; 19(6):226-233. PubMed ID: 30216639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
    Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
    Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
    Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Two-Institution Propensity Score-Matched Analysis.
    Ma SJ; Cummings M; Serra LM; Syed YA; Hermann GM; Chen Y; Milano MT; Singh AK; Gomez-Suescun JA; Singh DP
    Clin Lung Cancer; 2018 May; 19(3):e297-e302. PubMed ID: 29254649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.
    Kestin L; Grills I; Guckenberger M; Belderbos J; Hope AJ; Werner-Wasik M; Sonke JJ; Bissonnette JP; Xiao Y; Yan D;
    Radiother Oncol; 2014 Mar; 110(3):499-504. PubMed ID: 24630539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in stereotactic body radiation therapy for stage I small cell lung cancer.
    Stahl JM; Corso CD; Verma V; Park HS; Nath SK; Husain ZA; Simone CB; Kim AW; Decker RH
    Lung Cancer; 2017 Jan; 103():11-16. PubMed ID: 28024690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.